NABI BIOPHARMACEUTICALS : Cutera, Inc. (CUTR) 8.31

Profil supprimé

26 juin 2011 •11:36

Cutera, Inc. (CUTR) 8.31

CB 114M

Cash & Marketable investments 89.1M au 31/03

Price to Tangible Book 1.23

Shares Outstanding 13.72M

institutions 70%

Insiders 18%

Short Interest 7.40%

Price Target 12.33

4 fonds au dessus de 5% : Fidelity , GAMCO , Dimensional , BlackRock


____________________________________________________________________________ ____________________________


http://www.cutera.com/company/news-detail.php? id=200122

Kevin Connors, President and CEO of Cutera, stated, "In our first quarter we launched our Excel V vascular laser system at the American Academy of Dermatology meeting. Beginning in April 2011, we initiated commercial shipments of this product and we look forward to a continued ramp up of sales and marketing activities. The unfortunate disaster in Japan resulted in a delay in product deliveries to certain customers, as well as our ability to solicit new orders in the latter part of March. We will continue to monitor the business conditions in Japan closely."

"We believe that the following initiatives will put us on a stronger performance trajectory beginning in the second quarter of 2011:

The commencement of commercial shipments of our Excel V laser system;

The recent FDA clearance of our GenesisPlus product for onychomycosis (toenail fungus). We had been unable to initiate sales and marketing activities in our domestic market for this indication prior to receiving this clearance in April;

Our confidence in the leadership of our recently hired North American sales management team and the new growth strategies we put in place. We believe both will result in stronger performance for the balance of the year; and

Strengthening our research and development leadership with the addition of Len DeBenedictis as our Chief Technology Officer, who was hired in the first quarter of 2011."


Mr. Connors concluded, "We remain focused on key initiatives to increase future revenue levels and leverage our business model, which we expect will result in improved performance and cash flows in 2011, compared to 2010. We believe that our worldwide distribution network, strong balance sheet with approximately $96 million in cash and investments �C with no debt �C a broad portfolio of products, and various research and development projects underway, offer continuing, long-term opportunities for our company."


____________________________________________________________________________ ____________________________

GenesisPlus Receives FDA Clearance for Onychomycosis
Thursday, April 7,
2011

http://www.cutera.com/company/news-detail.php?id=200121

_____________ ________________________________________________________________________________ ___________

Cutera Announces CE Mark Approval for its Excel V Laser System
Thursday, May 12, 2011

http://www.cutera.com/company/news-detail.php?id=200123